(VIANEWS) – The NASDAQ opens in less than one hour and NeuroMetrix‘s pre-market value is already 4.98% up.
NeuroMetrix’s last close was $0.87, 81.69% below its 52-week high of $4.73.
The last session, NASDAQ ended with NeuroMetrix (NURO) rising 1.74% to $0.87. NASDAQ jumped 0.12% to $13,737.99, following the last session’s upward trend on what was a somewhat up trend exchanging session.
About NeuroMetrix
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.69.
Volume
Today’s last reported volume for NeuroMetrix is 35932 which is 70.26% below its average volume of 109400.
Moving Average
NeuroMetrix’s worth is way under its 50-day moving average of $0.99 and way below its 200-day moving average of $1.45.
More news about NeuroMetrix (NURO).
